Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant

Asan Medical Center

Status: Unknown

Conditions: Liver Transplant; Complications

Treatments: Procedure: LT

Study type: Observational

Funder types: Other

Identifiers

NCT04324255

2016-0031

Details and patient eligibility

About

In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been reported that a severe vWF/ADAMTS13 imbalance develops during liver transplantation (LT) and persists even after LT. Such changes are thought to contribute to postoperative thrombotic complications, which may lead to early adverse events of thrombotic microangiopathy after living-donor LT (LDLT). We investigated whether vWFPCR could predict EAD or graft failure following LT and compared it with FVIIIPCR, procoagulant, such as vWF and FVIII and anticoagulant, such as PC.

Enrollment: 1,199 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

patients who underwent LT

Exclusion criteria

deceased-donor liver transplant, and insufficient data, ABO-incompatible LT

Trial design

1,199 participants in 2 patient groups

Low ratio

Description:

Liver recipient with low preoperative von Willbrand factor-to-protein C ratio

Treatment:

Procedure: LT

High ratio

Description:

Liver recipient with high preoperative von Willbrand factor-to-protein C ratio

Treatment:

Procedure: LT